Comments on: Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study

Comments on: Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study http://www.iho100.com/en/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3/ 创新疗法的发现、开发和商业化的生物制药公司。 Thu, 16 Mar 2023 11:22:22 +0000 hourly 1 http://wordpress.org/?v=6.6.2